Why The Biggest IPO In Biotech History Could Have A Disruptive Impact

▤ Summary

Moderna stock popped Friday after an analyst rated it a buy, saying the biotech could launch a "disruptive class of medicines. Chardan analyst Gbola Amusa initiated coverage of Moderna stock with a buy rating and a 40 price target. The biotech is experimenting with messenger RNA , or mRNA, which carries genetic information from DNA to make proteins. "After demonstrating preclinical and clinical proof-of-concept in a number of indications, Moderna has attracted the attention of big pharma and has ongoing validating and de-risking collaborations with Merck ( MRK ) and AstraZeneca ( AZN )," he said. Modernas mRNA platform "offers the potential for disruptive solutions to important clinical problems," Amusa said.

▦ Linked Companies